Compounds > 2-amino-1-methylbenzimidazole
Page last updated: 2024-11-06

2-amino-1-methylbenzimidazole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-amino-1-methylbenzimidazole is a heterocyclic organic compound with a benzimidazole core structure. It has been investigated for its potential biological activity and its role in various chemical reactions. The compound is typically synthesized through a condensation reaction involving o-phenylenediamine and an appropriate carbonyl compound. Studies have explored its potential as a precursor for other heterocyclic systems and its ability to form coordination complexes with transition metals. The compound's unique structure and reactivity have led to investigations into its potential applications in areas such as drug development, catalysis, and material science.'

2-amino-1-methylbenzimidazole: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID74187
CHEMBL ID1232570
CHEBI ID194592
SCHEMBL ID149707
MeSH IDM0501993

Synonyms (45)

Synonym
BIDD:GT0052
2-amino-1-methyl-benzimidazole
1-methyl-1h-benzoimidazol-2-ylamine
BB 0241020
CHEMBL1232570
brn 0608298
1-methyl-1h-benzimidazol-2-amine
1-methyl-2-aminobenzimidazole
2-amino-1-methylbenzimidazole
ccris 4355
1h-benzimidazol-2-amine, 1-methyl-
OPREA1_009900
STK096886
2-amino-1-methylbenzimidazole, 95%
1-methyl-1h-1,3-benzodiazol-2-amine
bdbm14319
1622-57-7
AKOS000275856
ES7 ,
CHEBI:194592
1-methylbenzimidazol-2-amine
BBL013458
A810361
AM803285
FT-0633713
BRD-K20617646-001-01-0
1-methyl-1h-benzo[d]imidazol-2-amine
SCHEMBL149707
3KQT
mfcd00142855
1-methyl-1h-benzimidazol-2-ylamine
1-methyl-1,3-dihydro-benzoimidazol-2-ylideneamine
benzimidazole, 2-amino-1-methyl-
1-methyl-1h-benzimidazol-2-amine #
STR05341
DTXSID10167330
J-009915
F0266-0062
CS-0038976
1-methyl-1h-1,3-benzimidazol-2-amine
Q27460053
2-amino-1-methyl-1h-benzimidazole
EN300-99629
SY064124
Z56791928
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
benzimidazolesAn organic heterocyclic compound containing a benzene ring fused to an imidazole ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (17)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Membrane primary amine oxidase Rattus norvegicus (Norway rat)IC50 (µMol)80.00000.00600.50301.0000AID753428
Cationic trypsinBos taurus (cattle)Ki1,085.00000.00001.07539.0000AID1797191
Tryptase beta-2Homo sapiens (human)Ki1,085.00000.00101.05323.7000AID1797191
Membrane primary amine oxidaseHomo sapiens (human)IC50 (µMol)100.00000.02001.04004.1000AID753430
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Phenylethanolamine N-methyltransferaseHomo sapiens (human)Kd4.60004.6000234.7667690.0000AID977611
Chain A, Phenylethanolamine N-methyltransferaseHomo sapiens (human)Kd4.60004.6000234.7667690.0000AID977611
Chain A, Phenylethanolamine N-methyltransferaseHomo sapiens (human)Kd4.60004.6000234.7667690.0000AID977611
Chain A, Phenylethanolamine N-methyltransferaseHomo sapiens (human)Kd4.60004.6000234.7667690.0000AID977611
Chain A, Phenylethanolamine N-methyltransferaseHomo sapiens (human)Kd4.60004.6000234.7667690.0000AID977611
Chain A, Phenylethanolamine N-methyltransferaseHomo sapiens (human)Kd4.60004.6000234.7667690.0000AID977611
Chain A, Phenylethanolamine N-methyltransferaseHomo sapiens (human)Kd4.60004.6000234.7667690.0000AID977611
Chain A, Phenylethanolamine N-methyltransferaseHomo sapiens (human)Kd4.60004.6000234.7667690.0000AID977611
Chain A, Phenylethanolamine N-methyltransferaseHomo sapiens (human)Kd4.60004.6000234.7667690.0000AID977611
Chain A, Phenylethanolamine N-methyltransferaseHomo sapiens (human)Kd4.60004.6000234.7667690.0000AID977611
Chain A, Phenylethanolamine N-methyltransferaseHomo sapiens (human)Kd4.60004.6000234.7667690.0000AID977611
Chain A, Phenylethanolamine N-methyltransferaseHomo sapiens (human)Kd4.60004.6000234.7667690.0000AID977611
Chain A, Phenylethanolamine N-methyltransferaseHomo sapiens (human)Kd4.60004.6000234.7667690.0000AID977611
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (7)

Processvia Protein(s)Taxonomy
proteolysisCationic trypsinBos taurus (cattle)
digestionCationic trypsinBos taurus (cattle)
proteolysisTryptase beta-2Homo sapiens (human)
inflammatory responseMembrane primary amine oxidaseHomo sapiens (human)
cell adhesionMembrane primary amine oxidaseHomo sapiens (human)
amine metabolic processMembrane primary amine oxidaseHomo sapiens (human)
response to antibioticMembrane primary amine oxidaseHomo sapiens (human)
negative regulation of primary amine oxidase activityMembrane primary amine oxidaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (13)

Processvia Protein(s)Taxonomy
endopeptidase activityCationic trypsinBos taurus (cattle)
serine-type endopeptidase activityCationic trypsinBos taurus (cattle)
protein bindingCationic trypsinBos taurus (cattle)
metal ion bindingCationic trypsinBos taurus (cattle)
serpin family protein bindingCationic trypsinBos taurus (cattle)
serine-type endopeptidase activityTryptase beta-2Homo sapiens (human)
protein bindingTryptase beta-2Homo sapiens (human)
serine-type peptidase activityTryptase beta-2Homo sapiens (human)
copper ion bindingMembrane primary amine oxidaseHomo sapiens (human)
calcium ion bindingMembrane primary amine oxidaseHomo sapiens (human)
protein bindingMembrane primary amine oxidaseHomo sapiens (human)
primary amine oxidase activityMembrane primary amine oxidaseHomo sapiens (human)
identical protein bindingMembrane primary amine oxidaseHomo sapiens (human)
protein heterodimerization activityMembrane primary amine oxidaseHomo sapiens (human)
quinone bindingMembrane primary amine oxidaseHomo sapiens (human)
aliphatic amine oxidase activityMembrane primary amine oxidaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (11)

Processvia Protein(s)Taxonomy
serine protease inhibitor complexCationic trypsinBos taurus (cattle)
collagen-containing extracellular matrixTryptase beta-2Homo sapiens (human)
extracellular spaceTryptase beta-2Homo sapiens (human)
cytoplasmMembrane primary amine oxidaseHomo sapiens (human)
plasma membraneMembrane primary amine oxidaseHomo sapiens (human)
microvillusMembrane primary amine oxidaseHomo sapiens (human)
cell surfaceMembrane primary amine oxidaseHomo sapiens (human)
membraneMembrane primary amine oxidaseHomo sapiens (human)
early endosomeMembrane primary amine oxidaseHomo sapiens (human)
endoplasmic reticulumMembrane primary amine oxidaseHomo sapiens (human)
Golgi apparatusMembrane primary amine oxidaseHomo sapiens (human)
early endosomeMembrane primary amine oxidaseHomo sapiens (human)
plasma membraneMembrane primary amine oxidaseHomo sapiens (human)
endoplasmic reticulumMembrane primary amine oxidaseHomo sapiens (human)
Golgi apparatusMembrane primary amine oxidaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID1797191Enzyme Assay and Determination of the Inhibition Constants from Article 10.1021/bi060173m: \\Structure-guided design of peptide-based tryptase inhibitors.\\2006Biochemistry, May-16, Volume: 45, Issue:19
Structure-guided design of peptide-based tryptase inhibitors.
AID753428Inhibition of rat VAP-1 expressed in CHO cells using [14C]-benzylamine as substrate preincubated for 30 mins prior to substrate addition measured after 1 hr by scintillation spectrometric analysis2013Bioorganic & medicinal chemistry, Jul-01, Volume: 21, Issue:13
Novel 1H-imidazol-2-amine derivatives as potent and orally active vascular adhesion protein-1 (VAP-1) inhibitors for diabetic macular edema treatment.
AID753430Inhibition of human VAP-1 expressed in CHO cells using [14C]-benzylamine as substrate preincubated for 30 mins prior to substrate addition measured after 1 hr by scintillation spectrometric analysis2013Bioorganic & medicinal chemistry, Jul-01, Volume: 21, Issue:13
Novel 1H-imidazol-2-amine derivatives as potent and orally active vascular adhesion protein-1 (VAP-1) inhibitors for diabetic macular edema treatment.
AID1853099Binding affinity to PRMT5/MTA complex (unknown origin) by SPR analysis2022RSC medicinal chemistry, Dec-14, Volume: 13, Issue:12
Fragment optimization and elaboration strategies - the discovery of two lead series of PRMT5/MTA inhibitors from five fragment hits.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2010The Biochemical journal, Oct-01, Volume: 431, Issue:1
Fragment-based screening by X-ray crystallography, MS and isothermal titration calorimetry to identify PNMT (phenylethanolamine N-methyltransferase) inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (33.33)29.6817
2010's3 (50.00)24.3611
2020's1 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.64

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.64 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.59 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.64)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
adenine
[no description available]		2.05106-aminopurines;
purine nucleobase		Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine: mutagen from fried ground beef; structure given in first source. PhIP : An imidazopyridine that is 1H--imidazo[4,5-b]pyridine which is substituted at positions 1, 2, and 6 by methyl, amino, and phenyl groups, respectively. It is the most abundant of the mutagenic heterocyclic amines found in cooked meat and fish.		2.1110imidazopyridine;
primary amino compound		carcinogenic agent;
mutagen
benzimidazole
1H-benzimidazole : The 1H-tautomer of benzimidazole.		2.0810benzimidazole;
polycyclic heteroarene
methyl iodide
methyl iodide: RN given refers to unlabeled cpd with MF of CH3-I. iodomethane : A member of the class of iodomethanes that is methane in which one of the hydrogens is replaced by iodine.		2.0310iodomethanes;
methyl halides		fumigant insecticide
acetonitrile
acetonitrile: RN given refers to unlabeled cpd. acetonitrile : A nitrile that is hydrogen cyanide in which the hydrogen has been replaced by a methyl group.		7.0310aliphatic nitrile;
volatile organic compound		EC 3.5.1.4 (amidase) inhibitor;
NMR chemical shift reference compound;
polar aprotic solvent
quinoxalines
quinoxaline : A naphthyridine in which the nitrogens are at positions 1 and 4.		2.1110mancude organic heterobicyclic parent;
naphthyridine;
ortho-fused heteroarene
2-aminobenzothiazole
[no description available]		2.0810benzothiazoles
6-aminoquinoline
[no description available]		2.0510
1,2-Dihydroquinolin-2-imine
[no description available]		2.0310aminoquinoline
2-aminobenzimidazole
2-aminobenzimidazole: metabolite of benomyl; RN given refers to parent cpd. 2-aminobenzimidazole : A member of the class of benzimidazoles that is benzimidazole in which the hydrogen at position 2 is replaced by an amino group.		2.4620benzimidazolesmarine xenobiotic metabolite
phenylguanidine
phenylguanidine: RN given refers to parent cpd		2.0810
2,4-diaminoquinazoline
[no description available]		2.0310
4-hydroxyquinoline
4-quinolone : A quinolone that is 1,4-dihydroquinoline substituted by an oxo group at position 4.		2.4420monohydroxyquinoline;
quinolone
1-aminoisoquinoline
[no description available]		2.4420
3,4,8-trimethylimidazo(4,5-f)quinoxalin-2-amine
3,4,8-trimethylimidazo(4,5-f)quinoxalin-2-amine: structure given in first source		2.1110quinoxaline derivative
6-chloropurine
[no description available]		2.0510purines
ConditionIndicatedRelationship StrengthStudiesTrials
Alloxan Diabetes
[description not available]		02.0810
Central Retinal Edema, Cystoid
[description not available]		02.0810
Diabetic Retinopathy
Disease of the RETINA as a complication of DIABETES MELLITUS. It is characterized by the progressive microvascular complications, such as ANEURYSM, interretinal EDEMA, and intraocular PATHOLOGIC NEOVASCULARIZATION.		02.0810
Macular Edema
Fluid accumulation in the outer layer of the MACULA LUTEA that results from intraocular or systemic insults. It may develop in a diffuse pattern where the macula appears thickened or it may acquire the characteristic petaloid appearance referred to as cystoid macular edema. Although macular edema may be associated with various underlying conditions, it is most commonly seen following intraocular surgery, venous occlusive disease, DIABETIC RETINOPATHY, and posterior segment inflammatory disease. (From Survey of Ophthalmology 2004; 49(5) 470-90)		02.0810
Cancer of Prostate
[description not available]		02.1110
Prostatic Neoplasms
Tumors or cancer of the PROSTATE.		02.1110